170 related articles for article (PubMed ID: 36831540)
1. Targeted Degradation of Androgen Receptor by VNPP433-3β in Castration-Resistant Prostate Cancer Cells Implicates Interaction with E3 Ligase MDM2 Resulting in Ubiquitin-Proteasomal Degradation.
Thomas E; Thankan RS; Purushottamachar P; Weber DJ; Njar VCO
Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831540
[TBL] [Abstract][Full Text] [Related]
2. Novel AR/AR-V7 and Mnk1/2 Degrader, VNPP433-3β: Molecular Mechanisms of Action and Efficacy in AR-Overexpressing Castration Resistant Prostate Cancer In Vitro and In Vivo Models.
Thomas E; Thankan RS; Purushottamachar P; Huang W; Kane MA; Zhang Y; Ambulos NP; Weber DJ; Njar VCO
Cells; 2022 Aug; 11(17):. PubMed ID: 36078112
[TBL] [Abstract][Full Text] [Related]
3. Transcriptome profiling reveals that VNPP433-3β, the lead next-generation galeterone analog inhibits prostate cancer stem cells by downregulating epithelial-mesenchymal transition and stem cell markers.
Thomas E; Thankan RS; Purushottamachar P; Huang W; Kane MA; Zhang Y; Ambulos N; Weber DJ; Njar VCO
Mol Carcinog; 2022 Jul; 61(7):643-654. PubMed ID: 35512605
[TBL] [Abstract][Full Text] [Related]
4. MDM2 regulates the stability of AR, AR-V7, and TM4SF3 proteins in prostate cancer.
Khatiwada P; Rimal U; Han Z; Shemshedini L
Endocr Oncol; 2024 Jan; 4(1):e230017. PubMed ID: 38410785
[TBL] [Abstract][Full Text] [Related]
5. Salinization Dramatically Enhance the Anti-Prostate Cancer Efficacies of AR/AR-V7 and Mnk1/2 Molecular Glue Degraders, Galeterone and VNPP433-3β Which Outperform Docetaxel and Enzalutamide in CRPC CWR22Rv1 Xenograft Mouse Model.
Thankan RS; Thomas E; Purushottamachar P; Weber DJ; Njar VCO
Bioorg Chem; 2023 Oct; 139():106700. PubMed ID: 37392559
[TBL] [Abstract][Full Text] [Related]
6. Galeterone and The Next Generation Galeterone Analogs, VNPP414 and VNPP433-3β Exert Potent Therapeutic Effects in Castration-/Drug-Resistant Prostate Cancer Preclinical Models In Vitro and In Vivo.
Kwegyir-Afful AK; Ramalingam S; Ramamurthy VP; Purushottamachar P; Murigi FN; Vasaitis TS; Huang W; Kane MA; Zhang Y; Ambulos N; Tiwari S; Srivastava P; Nnane IP; Hussain A; Qiu Y; Weber DJ; Njar VCO
Cancers (Basel); 2019 Oct; 11(11):. PubMed ID: 31653008
[TBL] [Abstract][Full Text] [Related]
7. Targeting GRP78-dependent AR-V7 protein degradation overcomes castration-resistance in prostate cancer therapy.
Liao Y; Liu Y; Xia X; Shao Z; Huang C; He J; Jiang L; Tang D; Liu J; Huang H
Theranostics; 2020; 10(8):3366-3381. PubMed ID: 32206096
[No Abstract] [Full Text] [Related]
8. Proteostasis by STUB1/HSP70 complex controls sensitivity to androgen receptor targeted therapy in advanced prostate cancer.
Liu C; Lou W; Yang JC; Liu L; Armstrong CM; Lombard AP; Zhao R; Noel ODV; Tepper CG; Chen HW; Dall'Era M; Evans CP; Gao AC
Nat Commun; 2018 Nov; 9(1):4700. PubMed ID: 30446660
[TBL] [Abstract][Full Text] [Related]
9. SUMO3 modification by PIAS1 modulates androgen receptor cellular distribution and stability.
Yang N; Liu S; Qin T; Liu X; Watanabe N; Mayo KH; Li J; Li X
Cell Commun Signal; 2019 Nov; 17(1):153. PubMed ID: 31752909
[TBL] [Abstract][Full Text] [Related]
10. Androgen Receptor Modulation Optimized for Response-Splice Variant: A Phase 3, Randomized Trial of Galeterone Versus Enzalutamide in Androgen Receptor Splice Variant-7-expressing Metastatic Castration-resistant Prostate Cancer.
Taplin ME; Antonarakis ES; Ferrante KJ; Horgan K; Blumenstein B; Saad F; Luo J; de Bono JS
Eur Urol; 2019 Dec; 76(6):843-851. PubMed ID: 31542304
[TBL] [Abstract][Full Text] [Related]
11. Phosphorylation-dependent ubiquitylation and degradation of androgen receptor by Akt require Mdm2 E3 ligase.
Lin HK; Wang L; Hu YC; Altuwaijri S; Chang C
EMBO J; 2002 Aug; 21(15):4037-48. PubMed ID: 12145204
[TBL] [Abstract][Full Text] [Related]
12. Constant Degradation of the Androgen Receptor by MDM2 Conserves Prostate Cancer Stem Cell Integrity.
Vummidi Giridhar P; Williams K; VonHandorf AP; Deford PL; Kasper S
Cancer Res; 2019 Mar; 79(6):1124-1137. PubMed ID: 30626627
[TBL] [Abstract][Full Text] [Related]
13. Atypical E3 ligase ZFP91 promotes small-molecule-induced E2F2 transcription factor degradation for cancer therapy.
Liu TT; Yang H; Zhuo FF; Yang Z; Zhao MM; Guo Q; Liu Y; Liu D; Zeng KW; Tu PF
EBioMedicine; 2022 Dec; 86():104353. PubMed ID: 36375317
[TBL] [Abstract][Full Text] [Related]
14. Artemisinin disrupts androgen responsiveness of human prostate cancer cells by stimulating the 26S proteasome-mediated degradation of the androgen receptor protein.
Steely AM; Willoughby JA; Sundar SN; Aivaliotis VI; Firestone GL
Anticancer Drugs; 2017 Oct; 28(9):1018-1031. PubMed ID: 28708672
[TBL] [Abstract][Full Text] [Related]
15. p21-Activated kinase 6 (PAK6) inhibits prostate cancer growth via phosphorylation of androgen receptor and tumorigenic E3 ligase murine double minute-2 (Mdm2).
Liu T; Li Y; Gu H; Zhu G; Li J; Cao L; Li F
J Biol Chem; 2013 Feb; 288(5):3359-69. PubMed ID: 23132866
[TBL] [Abstract][Full Text] [Related]
16. Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer.
Lee CH; Ku JY; Ha JM; Bae SS; Lee JZ; Kim CS; Ha HK
Prostate; 2017 Jan; 77(1):60-71. PubMed ID: 27550197
[TBL] [Abstract][Full Text] [Related]
17. Bruceantin targets HSP90 to overcome resistance to hormone therapy in castration-resistant prostate cancer.
Moon SJ; Jeong BC; Kim HJ; Lim JE; Kim HJ; Kwon GY; Jackman JA; Kim JH
Theranostics; 2021; 11(2):958-973. PubMed ID: 33391515
[No Abstract] [Full Text] [Related]
18. DBC1 promotes castration-resistant prostate cancer by positively regulating DNA binding and stability of AR-V7.
Moon SJ; Jeong BC; Kim HJ; Lim JE; Kwon GY; Kim JH
Oncogene; 2018 Mar; 37(10):1326-1339. PubMed ID: 29249800
[TBL] [Abstract][Full Text] [Related]
19. Key Considerations in Targeted Protein Degradation Drug Discovery and Development.
Qin L; Dai H; Wang J
Front Chem; 2022; 10():934337. PubMed ID: 35978859
[TBL] [Abstract][Full Text] [Related]
20. The Steroidogenic Enzyme AKR1C3 Regulates Stability of the Ubiquitin Ligase Siah2 in Prostate Cancer Cells.
Fan L; Peng G; Hussain A; Fazli L; Guns E; Gleave M; Qi J
J Biol Chem; 2015 Aug; 290(34):20865-20879. PubMed ID: 26160177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
